Invention Reference Number
This technology addresses the need for improved antiviral agents by introducing a new class of small-molecule inhibitors that target the SARS-CoV-2 main protease through reversible, non-covalent interactions. Unlike many existing approaches, these inhibitors are designed to reduce unintended interactions with host proteins while maintaining strong activity against a highly conserved viral target. The result is a potential pathway toward antiviral therapeutics with improved specificity, reduced toxicity risk, and applicability across viral variants.
Description
Oak Ridge National Laboratory has developed a series of next-generation, non-covalent inhibitors designed to block the activity of the SARS-CoV-2 main protease, an enzyme essential for viral replication. This protease is highly conserved across known variants, making it an attractive and durable therapeutic target.
The disclosed compounds are fully reversible and non-peptidic, distinguishing them from many existing protease inhibitors that rely on covalent binding mechanisms and are peptidomimetic. By avoiding irreversible interactions, this approach is intended to reduce off-target effects and minimize interference with human proteases. By removing resemblance to peptides, this approach intends to increase chemical stability of the compounds to degradation by host enzymes. Structural and biochemical evaluation demonstrates that these inhibitors engage the viral protease through multiple non-covalent interactions, enhancing target specificity while maintaining antiviral activity.
The technology incorporates design strategies aimed at balancing potency, selectivity, and cellular activity, while avoiding chemical features commonly associated with instability or toxicity. Collectively, this work establishes a foundation for developing antiviral candidates with improved safety profiles and strong relevance to current and future coronavirus threats.
Benefits
- Reversible inhibition with reduced risk of off-target protein interactions
- High specificity for a conserved viral enzyme
- Potential for lower toxicity compared to covalent inhibitors
- Potential higher stability compared to peptidomimetic inhibitors
Applications and Industries
- Antiviral drug development
- Pharmaceutical research and development
- Infectious disease therapeutics
Contact
To learn more about this technology, email partnerships@ornl.gov or call 865-574-1051.
